v3.25.1
Basis of Presentation - Additional Information (Details)
1 Months Ended 3 Months Ended
Sep. 11, 2024
USD ($)
Feb. 25, 2024
USD ($)
$ / shares
Jul. 07, 2023
Sep. 30, 2024
USD ($)
Feb. 29, 2024
USD ($)
Mar. 31, 2025
USD ($)
$ / shares
shares
Mar. 31, 2024
USD ($)
Sep. 11, 2025
USD ($)
Dec. 31, 2024
USD ($)
$ / shares
shares
Subsidiary, Sale of Stock [Line Items]                  
Stock split ratio, common stock     0.071            
Common stock, shares authorized (in shares) | shares           107,142,857     107,142,857
Common stock, par value (in dollars per share) | $ / shares           $ 0.0001     $ 0.0001
Accumulated Deficit           $ 265,170,000     $ 268,195,000
Net cash used in operating activities           (5,925,000) $ (3,356,000)    
Financed insurance premiums           13,899,000     11,697,000
Cash and cash equivalents           16,310,000 $ 18,397,000   20,245,000
WTI Loan Facility | Term Loan                  
Subsidiary, Sale of Stock [Line Items]                  
Term loan facility $ 15,000,000                
Financed insurance premiums           5,088,000     4,819,000
WTI Loan Facility | Term Loan | First Tranche Commitment                  
Subsidiary, Sale of Stock [Line Items]                  
Term loan facility 10,000,000                
Proceeds from long-term borrowings           7,500,000      
ABL Line of Credit | Line of Credit                  
Subsidiary, Sale of Stock [Line Items]                  
Financed insurance premiums           $ 8,498,000     $ 6,263,000
ABL Line of Credit | Line of Credit | Revolving Credit Facility                  
Subsidiary, Sale of Stock [Line Items]                  
Maximum borrowing capacity 15,000,000                
ABL Line of Credit | Line of Credit | Revolving Credit Facility | Forecast                  
Subsidiary, Sale of Stock [Line Items]                  
Maximum borrowing capacity               $ 20,000,000  
Additional maximum borrowing capacity               $ 5,000,000  
September 2024 Offering                  
Subsidiary, Sale of Stock [Line Items]                  
Proceeds received from issuance of common stock       $ 10,590,000          
Consideration received $ 10,590,000                
Series B Convertible Preferred Stock | Private Placement                  
Subsidiary, Sale of Stock [Line Items]                  
Common stock, par value (in dollars per share) | $ / shares   $ 0.0001              
Proceeds from issuance of preferred stock, net of $0 and $158 of paid transaction costs, respectively   $ 9,250,000     $ 9,250,000